Back to News
Market Impact: 0.15
Teva Pharmaceutical Industries Limited - Depositary Receipt Price Target Increased by 19.98% to $0.13
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
The aggregate one-year analyst price target for Teva Pharmaceutical Industries' NYSE-listed depositary receipt was revised to $0.13 per share, up 19.98% from $0.11 on September 13, 2026. The update signals a modestly more favorable analyst outlook, though the article provides no underlying earnings, operating, or valuation rationale.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
TEVA0.35
More News
- Your health insurance premiums may take a big jump in 2027 — here's why
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Tesla reports 486,532 vehicle deliveries for third quarter, topping expectation
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Rivian tops Q3 delivery expectations, reconfirms 2026 guidance
- This hyperscaler made Goldman Sachs’ list of top picks for October
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Unstructured Data Search, Ask AI, and Advanced Futures Data
- Best AI Stock Research Tools for Professional Investors